1. Home
  2. AGIO vs QDEL Comparison

AGIO vs QDEL Comparison

Compare AGIO & QDEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$28.65

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo QuidelOrtho Corporation

QDEL

QuidelOrtho Corporation

HOLD

Current Price

$28.26

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGIO
QDEL
Founded
2007
1979
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
AGIO
QDEL
Price
$28.65
$28.26
Analyst Decision
Buy
Hold
Analyst Count
8
6
Target Price
$36.25
$40.00
AVG Volume (30 Days)
1.3M
921.4K
Earning Date
02-12-2026
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$44,791,000.00
$2,714,400,000.00
Revenue This Year
$27.83
N/A
Revenue Next Year
$134.79
$2.42
P/E Ratio
N/A
N/A
Revenue Growth
36.26
N/A
52 Week Low
$22.24
$19.50
52 Week High
$46.00
$46.24

Technical Indicators

Market Signals
Indicator
AGIO
QDEL
Relative Strength Index (RSI) 52.75 41.25
Support Level $26.25 $27.19
Resistance Level $28.87 $35.58
Average True Range (ATR) 1.09 2.18
MACD 0.25 -0.59
Stochastic Oscillator 74.29 13.42

Price Performance

Historical Comparison
AGIO
QDEL

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About QDEL QuidelOrtho Corporation

QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.

Share on Social Networks: